

Media release

Tecan implements new structure for global sales organization and appoints two new members of the Executive Board

- Three regional sales organizations to further increase momentum in the respective markets
- Matthias Düchting new regional head of sales and member of the Executive Board
- Frederic Vanderhaegen new Head of Business Unit Detection and member of the Executive Board

Männedorf, Switzerland, October 27, 2008 – Tecan Group AG (SWX: TECN) is implementing a new global sales organization structure, thus enabling it to better take regional differences into account and further increase momentum in the respective markets. The global sales organization is to be divided into three regions "Americas", "Europe & NEMEA" and "Greater Asia". As part of restructuring, the Board of Directors of Tecan Group AG has appointed Matthias Düchting to the Executive Board effective 1 December 2008. Matthias Düchting is to head sales for the "Europe & NEMEA" region, which covers the markets in Europe, Russia, the Middle East, Africa and India. Carl Severinghaus, who is returning to the US, is to remain a member of the Executive Committee and is responsible for the "Americas" region. The search for a sales head for "Greater Asia" is underway. The sales heads of the three regions will report directly to Thomas Bachmann, Tecan Group CEO.

Furthermore, Frederic Vanderhaegen is to replace Michael Illek as Head of BU Detection and is to become a member of the Executive Committee effective 1 December 2008. Michael Illek, who has successfully headed this BU since 2006, is resigning from the Executive Board for health reasons. He will assume new duties in R & D in Business Unit Detection.

Thomas Bachmann, Tecan CEO, commented, "In Matthias Düchting and Frederic Vanderhaegen, we are pleased to have gained two internationally very experienced life science managers for Tecan. The new sales organization structure will enable us to further increase the proximity to customers and markets in the different regions, and to react more flexibly and quickly to the various demands. In so doing, we aim to further increase momentum in the respective markets. Matthias Düchting will be able to make a significant contribution to this in the Europe & NEMEA region. We are very happy that Michael Illek is assuming new responsibilities in R & D in the Business Unit Detection. Frederic Vanderhaegen will continue to drive the Business Unit's healthy performance."

•TECAN•

2

From 2001 until the summer of 2008, Matthias Düchting was International Sales & Marketing Director and member of the Management of Hamilton AG (Bonaduz/Switzerland), where he was responsible for the Robotics Business Unit. From November 2006 until summer 2008, he simultaneously served as International Sales Director and member of the Management of Hamilton Medical AG. Prior to that, he held a number of different management positions in the life science industry at companies such as Bio-Rad, Sigma-Aldrich, Perseptive Biosystems and Perkin Elmer. Matthias Düchting is a graduate in biology. He is 46 years old and a German citizen.

From 1995 until fall 2008, Frederic Vanderhaegen worked for the US life science company Millipore in a variety of different countries; from 2005, he worked in Boston, Massachusetts, as North American Director, Sales & Service in the Bioscience Division. Prior to that, he held a research position at the Biochemical Process Department of the Meurice Institute in Belgium. Frederic Vanderhaegen is a chemical and biochemical engineer who also holds an MBA. He is 40 years old and a Belgian citizen.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2007, Tecan generated sales of CHF 414.4 million (USD 345.3 million; EUR 252.7 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).

For further information:

Tecan Group Dr. Rudolf Eugster Chief Financial Officer

investor@tecan.com www.tecan.com Martin Brändle Head of Corporate Communications & Investor Relations Tel. +41 (0) 44 922 84 30 Fax +41 (0) 44 922 88 89